Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment

  • Park, Chan Woo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine) ;
  • Choi, Min Hye (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine) ;
  • Yang, Kwang Moon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine) ;
  • Song, In Ok (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine)
  • Received : 2016.05.13
  • Accepted : 2016.08.18
  • Published : 2016.09.22
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To determine the preferred regimen for women with adenomyosis undergoing in vitro fertilization (IVF), we compared the IVF outcomes of fresh embryo transfer (ET) cycles with or without gonadotropin-releasing hormone (GnRH) agonist pretreatment and of frozenthawed embryo transfer (FET) cycles following GnRH agonist treatment. Methods: This retrospective study included 241 IVF cycles of women with adenomyosis from January 2006 to January 2012. Fresh ET cycles without (147 cycles, group A) or with (105 cycles, group B) GnRH agonist pretreatment, and FET cycles following GnRH agonist treatment (43 cycles, group C) were compared. Adenomyosis was identified by using transvaginal ultrasound at the initial workup and classified into focal and diffuse types. The IVF outcomes were also subanalyzed according to the adenomyotic region. Results: GnRH agonist pretreatment increased the stimulation duration ($11.5{\pm}2.1days$ vs. $9.9{\pm}2.0days$) and total dose of gonadotropin ($3,421{\pm}1,141IU$ vs. $2,588{\pm}1,192IU$), which resulted in a significantly higher number of retrieved oocytes ($10.0{\pm}8.2$ vs. $7.9{\pm}6.8$, p=0.013) in group B than in group A. Controlled ovarian stimulation for freezing resulted in a significantly higher number of retrieved oocytes ($14.3{\pm}9.2$ vs. $10.0{\pm}8.2$, p=0.022) with a lower dose of gonadotropin ($2,974{\pm}1,112IU$ vs. $3,421{\pm}1,141IU$, p=0.037) in group C than in group B. The clinical pregnancy rate in group C (39.5%) tended to be higher than those in groups B (30.5%) and A (25.2%) but without a significant difference. Conclusion: FET following GnRH agonist pretreatment tended to increase the pregnancy rate in patients with adenomyosis. Further largescale prospective studies are required to confirm this result.

Keywords

References

  1. Campo S, Campo V, Benagiano G. Infertility and adenomyosis. Obstet Gynecol Int 2012;2012:786132.
  2. Xiao Y, Li T, Xia E, Yang X, Sun X, Zhou Y. Expression of integrin ${\beta}3$ and osteopontin in the eutopic endometrium of adenomyosis during the implantation window. Eur J Obstet Gynecol Reprod Biol 2013;170:419-22. https://doi.org/10.1016/j.ejogrb.2013.05.007
  3. Fischer CP, Kayisili U, Taylor HS. HOXA10 expression is decreased in endometrium of women with adenomyosis. Fertil Steril 2011;95:1133-6. https://doi.org/10.1016/j.fertnstert.2010.09.060
  4. Martinez-Conejero JA, Morgan M, Montesinos M, Fortuno S, Meseguer M, Simon C, et al. Adenomyosis does not affect implantation, but is associated with miscarriage in patients undergoing oocyte donation. Fertil Steril 2011;96:943-50. https://doi.org/10.1016/j.fertnstert.2011.07.1088
  5. Mijatovic V, Florijn E, Halim N, Schats R, Hompes P. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI. Eur J Obstet Gynecol Reprod Biol 2010;151:62-5. https://doi.org/10.1016/j.ejogrb.2010.02.047
  6. Costello MF, Lindsay K, McNally G. The effect of adenomyosis on in vitro fertilisation and intra-cytoplasmic sperm injection treatment outcome. Eur J Obstet Gynecol Reprod Biol 2011;158:229-34. https://doi.org/10.1016/j.ejogrb.2011.04.030
  7. Niu Z, Chen Q, Sun Y, Feng Y. Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol 2013;29:1026-30. https://doi.org/10.3109/09513590.2013.824960
  8. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:511-21. https://doi.org/10.1016/j.bpobgyn.2006.01.016
  9. Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Hum Reprod 2014;29:964-77. https://doi.org/10.1093/humrep/deu041
  10. Kitawaki J, Noguchi T, Amatsu T, Maeda K, Tsukamoto K, Yamamoto T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57:514-9. https://doi.org/10.1095/biolreprod57.3.514
  11. Brosens J, Verhoeven H, Campo R, Gianaroli L, Gordts S, Hazekamp J, et al. High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome. Hum Reprod 2004;19:352-6. https://doi.org/10.1093/humrep/deh075
  12. Xiao Y, Sun X, Yang X, Zhang J, Xue Q, Cai B, et al. Leukemia inhibitory factor is dysregulated in the endometrium and uterine flushing fluid of patients with adenomyosis during implantation window. Fertil Steril 2010;94:85-9. https://doi.org/10.1016/j.fertnstert.2009.03.012
  13. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010;25:642-53. https://doi.org/10.1093/humrep/dep437
  14. Huang FJ, Kung FT, Chang SY, Hsu TY. Effects of short-course buserelin therapy on adenomyosis: a report of two cases. J Reprod Med 1999;44:741-4.
  15. Lin J, Sun C, Zheng H. Gonadotropin-releasing hormone agonists and laparoscopy in the treatment of adenomyosis with infertility. Chin Med J (Engl) 2000;113:442-5.
  16. Silva PD, Perkins HE, Schauberger CW. Live birth after treatment of severe adenomyosis with a gonadotropin-releasing hormone agonist. Fertil Steril 1994;61:171-2. https://doi.org/10.1016/S0015-0282(16)56471-1
  17. Ma WG, Song H, Das SK, Paria BC, Dey SK. Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation. Proc Natl Acad Sci U S A 2003;100:2963-8. https://doi.org/10.1073/pnas.0530162100
  18. Chen QJ, Sun XX, Li L, Gao XH, Gemzell-Danielsson K, Cheng LN. Effects of ovarian stimulation on endometrial integrin beta3 and leukemia inhibitory factor expression in the peri-implantation phase. Fertil Steril 2008;89(5 Suppl):1357-63. https://doi.org/10.1016/j.fertnstert.2007.03.073
  19. Togashi K, Ozasa H, Konishi I, Itoh H, Nishimura K, Fujisawa I, et al. Enlarged uterus: differentiation between adenomyosis and leiomyoma with MR imaging. Radiology 1989;171:531-4. https://doi.org/10.1148/radiology.171.2.2704819

Cited by

  1. New paradigms in the conservative surgical and interventional management of adenomyosis vol.29, pp.4, 2016, https://doi.org/10.1097/gco.0000000000000371
  2. Deferred Frozen Embryo Transfer: What Benefits can be Expected from this Strategy in Patients with and without Endometriosis? vol.9, pp.2, 2017, https://doi.org/10.5301/jeppd.5000281
  3. Clinical outcomes of infertility treatment for women with adenomyosis in Japan vol.16, pp.3, 2017, https://doi.org/10.1002/rmb2.12036
  4. Adenomyosis and IVF Outcomes - where we are and where we need to be vol.9, pp.3, 2017, https://doi.org/10.5301/jeppd.5000291
  5. Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options vol.25, pp.4, 2016, https://doi.org/10.1177/1933719118756754
  6. Window of Implantation is Significantly Displaced in Patients with Adenomyosis with Previous Implantation Failure as Determined by Endometrial Receptivity Assay vol.11, pp.4, 2018, https://doi.org/10.4103/jhrs.jhrs_52_18
  7. Effect of hypothyroidism on the hypothalamic–pituitary–ovarian axis and reproductive function of pregnant rats vol.18, pp.1, 2016, https://doi.org/10.1186/s12902-018-0258-y
  8. Modern approaches to the use of gonadotropin-releasing hormone agonists of assisted reproductive technologies vol.24, pp.2, 2018, https://doi.org/10.17116/repro201824275-82
  9. The rate of euploid miscarriage is increased in the setting of adenomyosis vol.2018, pp.3, 2018, https://doi.org/10.1093/hropen/hoy011
  10. Adenomyosis and IVF/ICSI treatment: clinical considerations and recommendations vol.13, pp.4, 2018, https://doi.org/10.1080/17446651.2018.1493923
  11. Administration of a GnRH agonist during the luteal phase frozen-thawed embryo transfer cycles: a meta-analysis vol.34, pp.11, 2016, https://doi.org/10.1080/09513590.2018.1480714
  12. Recent advances in understanding and managing adenomyosis vol.8, pp.None, 2016, https://doi.org/10.12688/f1000research.17242.1
  13. Uterine polyps, adenomyosis, leiomyomas, and endometrial receptivity vol.111, pp.4, 2016, https://doi.org/10.1016/j.fertnstert.2019.02.008
  14. Should we still perform fresh embryo transfers in ART? vol.34, pp.12, 2016, https://doi.org/10.1093/humrep/dez233
  15. The Future of Cryopreservation in Assisted Reproductive Technologies vol.11, pp.None, 2016, https://doi.org/10.3389/fendo.2020.00067
  16. Impact of Gonadotropin-Releasing Hormone Agonist Pre-treatment on the Cumulative Live Birth Rate in Infertile Women With Adenomyosis Treated With IVF/ICSI: A Retrospective Cohort Study vol.11, pp.None, 2016, https://doi.org/10.3389/fendo.2020.00318
  17. Diagnosing adenomyosis: an integrated clinical and imaging approach vol.26, pp.3, 2016, https://doi.org/10.1093/humupd/dmz049
  18. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a systematic review and meta-analysis vol.42, pp.1, 2021, https://doi.org/10.1016/j.rbmo.2020.09.023
  19. Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study vol.12, pp.None, 2016, https://doi.org/10.3389/fendo.2021.609771
  20. Impact of Uterine Adenomyosis on Pregnancy Outcomes in Women Undergoing In Vitro Fertilization Treated With a Long-Term Pituitary Downregulation Protocol vol.12, pp.None, 2016, https://doi.org/10.3389/fendo.2021.655803
  21. The freeze-all strategy after IVF: which indications? vol.42, pp.3, 2016, https://doi.org/10.1016/j.rbmo.2020.11.013
  22. Pregnancy outcome and cost‐effectiveness comparisons of artificial cycle‐prepared frozen embryo transfer with or without GnRH agonist pretreatment for polycystic ovary syndrome: a random vol.128, pp.4, 2016, https://doi.org/10.1111/1471-0528.16461
  23. Serum levels of cancer antigen 125 before hormone replacement therapy are not associated with clinical outcome of frozen embryo transfer in women with adenomyosis vol.49, pp.4, 2016, https://doi.org/10.1177/03000605211005878
  24. Influence of nodular and severe forms of diffuse adenomyosis on reproductive function: a review of reproductive outcomes of surgical interventions and IVF vol.6, pp.3, 2016, https://doi.org/10.29413/abs.2021-6.3.3
  25. Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists vol.18, pp.19, 2016, https://doi.org/10.3390/ijerph18199941
  26. Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach vol.10, pp.21, 2021, https://doi.org/10.3390/jcm10214878
  27. Recent Advances and Current Perspectives on Endometrial Receptivity vol.10, pp.4, 2016, https://doi.org/10.1007/s13669-021-00313-4
  28. Effects of ammonia on hypothalamic-pituitary-ovarian axis in female rabbits vol.227, pp.None, 2016, https://doi.org/10.1016/j.ecoenv.2021.112922
  29. Pretreatment with a GnRH agonist and hormone replacement treatment protocol could not improve live birth rate for PCOS women undergoing frozen-thawed embryo transfer cycles vol.21, pp.1, 2021, https://doi.org/10.1186/s12884-021-04293-4